Author:
Dimopoulos Meletios A,Trotman Judith,Tedeschi Alessandra,Matous Jeffrey V,Macdonald David,Tam Constantine,Tournilhac Olivier,Ma Shuo,Oriol Albert,Heffner Leonard T,Shustik Chaim,García-Sanz Ramón,Cornell Robert F,de Larrea Carlos Fernández,Castillo Jorge J,Granell Miquel,Kyrtsonis Marie-Christine,Leblond Veronique,Symeonidis Argiris,Kastritis Efstathios,Singh Priyanka,Li Jianling,Graef Thorsten,Bilotti Elizabeth,Treon Steven,Buske Christian
Reference26 articles.
1. Waldenström's macroglobulinemia: an indolent B-cell lymphoma with distinct molecular and clinical features;Treon;Hematol Oncol,2013
2. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus;Dimopoulos;Blood,2014
3. How to manage Waldenström's macroglobulinemia;Buske;Leukemia,2013
4. Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in patients with relapsed Waldenström's macroglobulinemia: development of a large observational Pan-European data platform. The 21st European Hematology Association Annual Congress; Copenhagen, Denmark; June 9–12, 2016. Abstr E1275.
5. Rituximab intolerance in patients with Waldenström macroglobulinaemia;Castillo;Br J Haematol,2016